Q&A with Erik van den Berg, AM-Pharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Erik van den Berg, AM-Pharma
A Q&A with Erik van den Berg, CEO of AM-Pharma, on recent industry trends.

Pharmaceutical Technology
Volume 36, Issue 4, pp. 144

PharmTech:
How has the increasing focus on biopharmaceuticals affected your business?



Van den Berg:
AM-Pharma is solely focused on biopharmaceuticals. We have established proof-of-concept data with bovine alkaline phosphatase in the treatment of acute kidney injury. Now, we will manufacture recombinant human alkaline phosphatase and perform subsequent clinical studies with this recombinant material.

PharmTech:
How will the industry remain innovative as it reduces spending on research?

Van den Berg:
The large pharmaceutical companies have become dependent on external R&D. More than 50% of the clinical pipeline is derived from small biotech or academia. The reduced spending on research should be supplemented with higher investment in development and acquisition/licensing expenses.

PharmTech:
Do you see a new industry trend emerging?

Van den Berg:
The industry trend is towards more and more outsourcing of development activities.

PharmTech:
How is your company responding to regulators' intensifying emphasis on inspections and product quality?

Van den Berg:
Our quality system is aligned with industry expectations, which means that collaborations are managed by quality agreements and involve regular inspections. In addition, we maintain contact with the regulatory authorities early on in the development program to include their requests and recommendations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
28%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
33%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here